{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T19:21:34Z","timestamp":1794424894146,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s40265-018-0929-z","type":"journal-article","created":{"date-parts":[[2018,6,9]],"date-time":"2018-06-09T06:01:20Z","timestamp":1528524080000},"page":"929-940","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":86,"title":["Sarilumab: A Review in Moderate to Severe Rheumatoid Arthritis"],"prefix":"10.1007","volume":"78","author":[{"given":"Yvette N.","family":"Lamb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,9]]},"reference":[{"key":"929_CR1","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.2147\/DDDT.S100302","volume":"11","author":"MG Raimondo","year":"2017","unstructured":"Raimondo MG, Biggioggero M, Crotti C, et al. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. Drug Des Dev Ther. 2017;11:1593\u2013603.","journal-title":"Drug Des Dev Ther."},{"issue":"6","key":"929_CR2","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"929_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/art.39480","volume":"68","author":"JA Singh","year":"2016","unstructured":"Singh JA, Saag KG, Bridges SLJ, et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Rheumatol. 2016;68(1):1\u201326.","journal-title":"Arthritis Rheumatol."},{"issue":"1","key":"929_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1111\/j.1749-6632.2009.04621.x","volume":"1173","author":"A Marchesoni","year":"2009","unstructured":"Marchesoni A, Zaccara E, Gorla R, et al. TNF-\u03b1 antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. Ann N Y Acad Sci. 2009;1173(1):837\u201346.","journal-title":"Ann N Y Acad Sci"},{"issue":"5","key":"929_CR5","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1177\/1759720X10378372","volume":"2","author":"S Srirangan","year":"2010","unstructured":"Srirangan S, Choy CH. The role of interleukin 6 in the pathophysiology of rheumatoid arthritis. Ther Adv Musculoskel Dis. 2010;2(5):247\u201356.","journal-title":"Ther Adv Musculoskel Dis."},{"key":"929_CR6","unstructured":"Regeneron Pharmaceuticals Inc., Sanofi-Aventis U.S. LLC. Prescribing information for Kevzara\u00ae (sarilumab) injection, for subcutaneous use. 2017. http:\/\/products.sanofi.us\/ . Accessed 29 May 2018."},{"key":"929_CR7","unstructured":"European Medicines Agency. Kevzara: summary of product characteristics 2017. http:\/\/www.ema.europa.eu\/ . Accessed 29 May 2018."},{"issue":"Suppl","key":"929_CR8","first-page":"S69","volume":"26","author":"T Potocky","year":"2016","unstructured":"Potocky T, Rafique A, Fairhurst J, et al. Evaluation of the binding kinetics and functional bioassay activity of sarilumab and tocilizumab to the human il-6 receptor alpha (il-6r\u03b1) [abstract no. ICW-C15-3]. Mod Rheumatol. 2016;26(Suppl):S69\u201370.","journal-title":"Mod Rheumatol"},{"key":"929_CR9","unstructured":"European Medicines Agency. Kevzara: CHMP assessment report. 2017. http:\/\/www.ema.europa.eu\/ . Accessed 29 May 2018."},{"issue":"Suppl 10","key":"929_CR10","first-page":"3336","volume":"67","author":"M Dougados","year":"2015","unstructured":"Dougados M, Choy EH, Kameda H, et al. IL-6R blockade with sarilumab plus methotrexate results in changes in clinical and laboratory parameters associated with chronic inflammation in patients with moderate-to-severe RA in a phase 3 study [abstract no. 2761]. Arthritis Rheumatol. 2015;67(Suppl 10):3336\u20138.","journal-title":"Arthritis Rheumatol."},{"issue":"Suppl 10","key":"929_CR11","first-page":"2615","volume":"68","author":"C Gabay","year":"2016","unstructured":"Gabay C, Msihid J, Daskalakis N, et al. Effect of sarilumab on circulating biomarkers of bone and joint destruction in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors [abstract no. 2615]. Arthritis Rheumatol. 2016;68(Suppl 10):2615.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"929_CR12","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1136\/annrheumdis-2017-eular.4534","volume":"76","author":"C Gabay","year":"2017","unstructured":"Gabay C, Msihid J, Paccard C, et al. Sarilumab significantly suppresses circulating biomarkers of bone resorption and cardiovascular risk compared with adalimumab: biomarker analysis from the phase 3 MONARCH study [abstract no. FRI0227]. Ann Rheum Dis. 2017;76(Suppl 2):570.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"929_CR13","first-page":"1268","volume":"67","author":"P Emery","year":"2015","unstructured":"Emery P, Rondon J, Garg A, et al. Safety and tolerability of subcutaneous sarilumab compared to intravenous tocilizumab in patients with RA [abstract no. 971]. Arthritis Rheumatol. 2015;67(Suppl 10):1268\u20139.","journal-title":"Arthritis Rheumatol."},{"key":"929_CR14","unstructured":"Kovalenko P, Paccaly A, Boyapati A, et al. Pharmacodynamic (PD) model of neutrophil margination to describe transient effect of sarilumab on absolute neutrophil count (ANC) in patients with rheumatoid arthritis (RA) after single-dose administration [abstract no. 7284 and poster III-58]. In: Annual meeting of the population approach group in Europe. 2017."},{"issue":"1","key":"929_CR15","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1186\/s13075-016-1132-9","volume":"18","author":"A Boyapati","year":"2016","unstructured":"Boyapati A, Msihid J, Fiore S, et al. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY. Arthritis Res Ther. 2016;18(1):225.","journal-title":"Arthritis Res Ther."},{"issue":"5","key":"929_CR16","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76(5):840\u20137.","journal-title":"Ann Rheum Dis"},{"key":"929_CR17","unstructured":"Xu C, Su Y, Paccaly A, et al. Population pharmacokinetics of sarilumab in patients with rheumatoid arthritis [abstract no. 7283]. In: Annual meeting of the population approach group in Europe. 2017."},{"issue":"6","key":"929_CR18","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40262-016-0462-8","volume":"56","author":"EB Lee","year":"2017","unstructured":"Lee EB, Daskalakis N, Xu C, et al. Disease-drug interaction of sarilumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacokinet. 2017;56(6):607\u201315.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"929_CR19","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.39944","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277\u201390.","journal-title":"Arthritis Rheumatol."},{"issue":"6","key":"929_CR20","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424\u201337.","journal-title":"Arthritis Rheumatol."},{"key":"929_CR21","unstructured":"Sanofi. A study assessing the efficacy and safety of sarilumab added to MTX in Japanese patients with moderately to severely active rheumatoid arthritis (SARIL-RA-KAKEHASI) [ClinicalTrials.gov identifier NCT02293902] US National Institutes of Health, ClinicalTrials.gov. 2017. http:\/\/www.clinicaltrials.gov\/ . Accessed 29 May 2018."},{"key":"929_CR22","unstructured":"Sanofi. Long term evaluation of sarilumab in rheumatoid arthritis patients (SARIL-RA-EXTEND) [ClinicalTrials.gov identifier NCT01146652] US National Institutes of Health, ClinicalTrials.gov. 2017. http:\/\/clinicaltrials.gov\/ . Accessed 29 May 2018."},{"issue":"Suppl 10","key":"929_CR23","first-page":"2482","volume":"69","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Fiore S, Hu C-C, et al. Efficacy and safety of switching from adalimumab to sarilumab in an open-label extension of a phase 3 monotherapy trial in patients with active rheumatoid arthritis [abstract no. 2482]. Arthritis Rheumatol. 2017;69(Suppl 10):2482.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"929_CR24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1136\/annrheumdis-2017-eular.4540","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Mangan EK, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy in patients with active rheumatoid arthritis in the phase 3 MONARCH study, including subpopulations [abstract no. SAT0202]. Ann Rheum Dis. 2017;76(Suppl 2):849.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"929_CR25","first-page":"2468","volume":"69","author":"P Emery","year":"2017","unstructured":"Emery P, van Hoogstraten H, Jayawardena S, et al. Efficacy of sarilumab in patients with rheumatoid arthritis who previously received sarilumab or tocilizumab [abstract no. 2468]. Arthritis Rheumatol. 2017;69(Suppl 10):2468.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"929_CR26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1136\/annrheumdis-2017-eular.5155","volume":"76","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, Hrycaj P, van Hoogstraten H, et al. Sarilumab dose reduction in an open-label extension study in RA patients with inadequate response to TNF inhibitors [abstract no. SAT0212]. Ann Rheum Dis. 2017;76(Suppl 2):853.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"929_CR27","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1136\/annrheumdis-2016-eular.3133","volume":"75","author":"R Fleischmann","year":"2016","unstructured":"Fleischmann R, Mangan EK, van Adelsberg J, et al. Onset of action of sarilumab in patients with rheumatoid arthritis in 2 phase 3 studies [abstract no. SAT0180]. Ann Rheum Dis. 2016;75(Suppl 2):733.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 10","key":"929_CR28","first-page":"1632","volume":"68","author":"M Genovese","year":"2016","unstructured":"Genovese M, Fleischmann R, Mangan E, et al. Efficacy and safety of sarilumab in subgroups of patients with rheumatoid arthritis from 2 phase 3 studies [abstract no. 1632]. Arthritis Rheumatol. 2016;68(Suppl 10):1632.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 10","key":"929_CR29","first-page":"1631","volume":"68","author":"MC Genovese","year":"2016","unstructured":"Genovese MC, Fay J, Parrino J, et al. Sarilumab dose reduction in an open-label extension study in RA patients [abstract no. 1631]. Arthritis Rheumatol. 2016;68(Suppl 10):1631.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl","key":"929_CR30","first-page":"S97","volume":"27","author":"Y Tanaka","year":"2017","unstructured":"Tanaka Y, Sato M, Sumi M, et al. Efficacy of sarilumab, human anti\u2013IL-6 receptor monoclonal antibody in KAKEHASI study, phase 3 trial for Japanese rheumatoid arthritis patients [abstract no. W13-2]. Mod Rheumatol. 2017;27(Suppl):S97.","journal-title":"Mod Rheumatol"},{"issue":"Suppl 10","key":"929_CR31","first-page":"1633","volume":"68","author":"D van der Heijde","year":"2016","unstructured":"van der Heijde D, van Adelsberg J, van Hoogstraten H, et al. Clinical and radiographic outcomes after 3\u00a0years of sarilumab in patients with rheumatoid arthritis [abstract no. 1633]. Arthritis Rheumatol. 2016;68(Suppl 10):1633.","journal-title":"Arthritis Rheumatol"},{"key":"929_CR32","unstructured":"Sanofi, Regeneron. Human anti-IL-6 receptor monoclonal antibody: Kevzara\u00ae subcutaneous injection (150\u00a0mg and 200\u00a0mg) 2017. http:\/\/www.pmda.go.jp\/ . Accessed 29 May 2018."},{"issue":"9","key":"929_CR33","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1136\/annrheumdis-2013-204405","volume":"73","author":"TW Huizinga","year":"2014","unstructured":"Huizinga TW, Fleischmann RM, Jasson M, et al. Sarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73(9):1626\u201334.","journal-title":"Ann Rheum Dis"},{"key":"929_CR34","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/s13075-016-1096-9","volume":"18","author":"V Strand","year":"2016","unstructured":"Strand V, Kosinski M, Chen CI, et al. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. Arthritis Res Ther. 2016;18:198.","journal-title":"Arthritis Res Ther."},{"issue":"1","key":"929_CR35","doi-asserted-by":"publisher","first-page":"e000416","DOI":"10.1136\/rmdopen-2016-000416","volume":"3","author":"V Strand","year":"2017","unstructured":"Strand V, Reaney M, Chen CI, et al. Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response\/intolerance to tumour necrosis factor inhibitors. RMD Open. 2017;3(1):e000416.","journal-title":"RMD Open."},{"key":"929_CR36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key121","author":"MC Genovese","year":"2018","unstructured":"Genovese MC, van Adelsberg J, Fan C, et al. Two years of sarilumab in patients with rheumatoid arthritis and an inadequate response to MTX: safety, efficacy and radiographic outcomes. Rheumatology (Oxford). 2018. https:\/\/doi.org\/10.1093\/rheumatology\/key121 .","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl","key":"929_CR37","first-page":"S97","volume":"27","author":"H Kameda","year":"2017","unstructured":"Kameda H, Sato M, Sumi M, et al. Safety of sarilumab, a novel human anti\u2013IL-6 receptor monoclonal antibody: safety outcome at 24\u00a0weeks in placebo-controlled double-blind study for Japanese rheumatoid arthritis patients (KAKEHASI study) [abstract no. W13-3]. Mod Rheumatol. 2017;27(Suppl):S97.","journal-title":"Mod Rheumatol"},{"key":"929_CR38","unstructured":"American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Appendix 5: executive summary. 2015. http:\/\/www.rheumatology.org\/ . Accessed 29 May 2018."},{"key":"929_CR39","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1136\/ard.2006.068064","volume":"66","author":"N Nishimoto","year":"2007","unstructured":"Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"929_CR40","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/rheumatology\/keu035","volume":"53","author":"HL Wright","year":"2014","unstructured":"Wright HL, Cross AL, Edwards SW, et al. Effects of IL-6 and IL-6 blockade on neutrophil function in vitro and in vivo. Rheumatology (Oxford). 2014;53(7):1321\u201331.","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"929_CR41","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"GM Bartelds","year":"2007","unstructured":"Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: the relationship with anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921\u20136.","journal-title":"Ann Rheum Dis"},{"key":"929_CR42","unstructured":"European Medicines Agency. RoActemra 20\u00a0mg\/ml concentrate for solution for infusion: summary of product characteristics. 2017. http:\/\/www.ema.europa.eu\/ . Accessed 29 May 2018."},{"issue":"10","key":"929_CR43","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1080\/14712598.2016.1217988","volume":"16","author":"RR June","year":"2016","unstructured":"June RR, Olsen NJ. Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther. 2016;16(10):1303\u20139.","journal-title":"Expert Opin Biol Ther."},{"key":"929_CR44","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","volume":"36","author":"PC Taylor","year":"2016","unstructured":"Taylor PC, Moore A, Vasilescu R, et al. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int. 2016;36:685\u201395.","journal-title":"Rheumatol Int"},{"issue":"Suppl 10","key":"929_CR45","first-page":"2457","volume":"69","author":"M Fournier","year":"2017","unstructured":"Fournier M, Chen C-I, Kuznik A, et al. Sarilumab for the treatment of active, moderate-to-severe rheumatoid arthritis (RA): an analysis of cost per effectively treated patient [abstract no. 2457]. Arthritis Rheumatol. 2017;69(Suppl 10):2457.","journal-title":"Arthritis Rheumatol"},{"key":"929_CR46","first-page":"177","volume":"25","author":"A Rischin","year":"2017","unstructured":"Rischin A, \u00d6st\u00f6r AJK. Update on biosimilars in rheumatology. Immunopharmacology. 2017;25:177\u201384.","journal-title":"Immunopharmacology"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-018-0929-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0929-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-018-0929-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T21:51:11Z","timestamp":1751665871000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-018-0929-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":46,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["929"],"URL":"https:\/\/doi.org\/10.1007\/s40265-018-0929-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"9 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Yvette Lamb and Emma Deeks are salaried employees of Adis\/Springer, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}